Tscan Therapeutics计划于2026年下半年启动TSC-102双候选药物I期临床试验

美股速递
Feb 26

生物技术公司Tscan Therapeutics近日宣布,其研发管线中的重要候选药物TSC-102已确定临床开发时间表。根据最新规划,公司预计在2026年下半年正式启动针对TSC-102两项适应症的I期临床试验。

这一进展标志着Tscan Therapeutics在肿瘤免疫治疗领域迈出关键一步。TSC-102作为公司核心研发项目,其临床试验的推进将为企业未来发展注入新动力。业界普遍关注该药物在实体瘤治疗方面的潜在突破,预计相关研究数据将为后续开发提供重要依据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10